EUVIMEDFaigh amach EUVIMED
Leserbrief

Comment response in: ‘Systemic allergic contact dermatitis after use of topical nitrofurazone’

Elena Beatriz Sanz-Cabanillas, Lucía de Dulanto-García, Álvaro Prados-Carmona iD, Francisco J Navarro-Triviño iD

Contact Dermatitis · 2024

DOI: 10.1111/cod.14634 ↗

At a glance

Leserbrief in Contact Dermatitis, 2024. Written by Elena Beatriz Sanz-Cabanillas and 3 co-authors. Institution: Dermatology Service, Costa del Sol Hospital, Marbella, Spain. Major MEDLINE topics: Dermatitis, Allergic Contact, Nitrofurazone. 4 references.

AchoimreSubjectsSonraí leabharliostaCiteRelated studies

Abstract (original language)

Systemic contact dermatitis (SCD) has been known by various names over the years (e.g., Baboon Syndrome, SDRIFE, non-pigmented fixed drug eruption, intertriginous drug rash and drug-induced intertrigo). Currently, the term SCD is believed to encompass a range of clinical presentations (eczematous eruption, dyshidrotic eczema, maculopapular eruption, erythroderma, intertriginous and flexural exanthema) with or without systemic symptoms. This cutaneous reaction occurs following re-exposure to a hapten (e.g., drug, metal and plant) via systemic routes. Systemic exposure can occur through oral, rectal, intravesical, intravenous, inhaled or transcutaneous routes.1 In cases of transcutaneous drug exposure, dermatitis typically begins at the site of application and is followed by an eczematous eruption in other areas.2 The pathogenic mechanism responsible for systemic dissemination is thought to involve hematogenous spread. However, this mechanism may vary for different clinical forms and depends on the characteristics of the drug involved. It is established that a delayed reaction mediated by T lymphocytes occurs, though other immunological mechanisms involved remain unknown.3 We present a case of systemic contact dermatitis due to transcutaneous exposure to Nitrofurazone (Furacin®) used as a treatment for a forearm burn. In our case, the patient exhibited prior sensitization to Nitrofurazone (Furacin®). The patient developed eczema at the site of cream application, followed by eczematous lesions in regions distant from the initial site. Through anamnesis, we ruled out the application of the topical Furacin® preparation to these regions by the patient. We hypothesize that the damaged skin (burn) along with occlusion facilitated drug absorption and subsequent hematogenous dissemination. However, we cannot rule out the possibility that specific T lymphocytes were stimulated and migrated hematogenously to other regions rather than the drug itself. It is known that positive patch test reactions to polyethylene glycol can appear on day 4 or later. Nevertheless, we ruled out sensitization to polyethylene glycol due to the absence of a delayed reaction (beyond day 4). While nitrofurazone allergy can promote sensitization to polyethylene glycol in many cases, this was not observed in our case.4 Elena Beatriz Sanz-Cabanillas: Writing – original draft; investigation; validation; writing – review and editing. Lucía de Dulanto-García: Writing – review and editing; investigation. Álvaro Prados-Carmona: Investigation; writing – original draft; writing – review and editing; visualization; validation. Francisco J. Navarro-Triviño: Methodology; validation; visualization; writing – review and editing; investigation; conceptualization. The authors declare no conflicts of interest. Informed consent has been obtained from the patient for the use of the photographs (they do not allow identification).

Subjects

MeSH terms (MEDLINE)

Dermatitis, Allergic ContactNitrofurazoneHumansPatch Tests

Substances

Nitrofurazone

Authors and institutions

  • Dermatology Service, Costa del Sol Hospital, Marbella, Spain.
  • Allergology Service, Hospital Universitario San Cecilio, Granada, Spain.
  • Department of Contact Eczema and Immunoallergic Diseases, Dermatology, Hospital Universitario San Cecilio, Granada, Spain.

ORCID profiles: Álvaro Prados-Carmona, Francisco J Navarro-Triviño

Cite

APA

Sanz-Cabanillas, E. B., de Dulanto-García, L., Prados-Carmona, Á., & Navarro-Triviño, F. J. (2024). Comment response in: ‘Systemic allergic contact dermatitis after use of topical nitrofurazone’. Contact Dermatitis. https://doi.org/10.1111/cod.14634

Vancouver

Sanz-Cabanillas EB, de Dulanto-García L, Prados-Carmona Á, Navarro-Triviño FJ. Comment response in: ‘Systemic allergic contact dermatitis after use of topical nitrofurazone’. Contact Dermatitis. 2024. doi:10.1111/cod.14634

BibTeX
@article{SanzCabanillas2024,
  author = {Sanz-Cabanillas, Elena Beatriz and de Dulanto-García, Lucía and Prados-Carmona, Álvaro and Navarro-Triviño, Francisco J},
  title = {Comment response in: ‘Systemic allergic contact dermatitis after use of topical nitrofurazone’},
  journal = {Contact Dermatitis},
  year = {2024},
  doi = {10.1111/cod.14634}
}
Start for free →